Author

Shengjian Huang

Institution: Shenzhen Chipscreen Biosciences Co.

Observed institution: Shenzhen Chipscreen Biosciences Co.

ORCID: 0000-0002-4666-3788

Observed ORCID: 0000-0002-4666-3788

OpenAlex ID: A5085656751

Discovery of a novel, liver-targeted thyroid hormone receptor-β agonist, CS271011, in the treatment of lipid metabolism disorders

2023 · Suwen Lin, Shengjian Huang, et al. · Frontiers in Endocrinology · 14

CS27109, A Selective Thyroid Hormone Receptor-β Agonist Alleviates Metabolic-Associated Fatty Liver Disease in Murine Models

2023 · Shengjian Huang, Zhou Deng, et al. · International Journal of Endocrinology · 11

Targeting ASK1 by CS17919 alleviates kidney‐ and liver‐related diseases in murine models

2024 · Guoqiang Liao, Qianjiao Yang, et al. · Animal Models and Experimental Medicine · 2

Chiglitazar Demonstrates Potential to Treat Metabolic Dysfunction–Associated Steatohepatitis In Vitro and In Vivo

2026 · Liushan Wei, Sijun Deng, et al. · Current Drug Metabolism · 1

A novel mouse model of idiopathic pulmonary fibrosis established by in situ lung injection of bleomycin

2026 · Guoqiang Liao, Lei Qu, et al. · Research Square

CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1

2025 · Heping Jin, Zongyang Li, et al. · Advanced Biology

Works count: 6

Citation count: 28

H-index: 2

I10-index: 2